MXPA03000368A - Derivados de pirrolidina como inhibidores de metalproteasa. - Google Patents

Derivados de pirrolidina como inhibidores de metalproteasa.

Info

Publication number
MXPA03000368A
MXPA03000368A MXPA03000368A MXPA03000368A MXPA03000368A MX PA03000368 A MXPA03000368 A MX PA03000368A MX PA03000368 A MXPA03000368 A MX PA03000368A MX PA03000368 A MXPA03000368 A MX PA03000368A MX PA03000368 A MXPA03000368 A MX PA03000368A
Authority
MX
Mexico
Prior art keywords
pyrrolidine derivatives
metalloprotease inhibitors
compounds
inhibitors
zinc
Prior art date
Application number
MXPA03000368A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Chucholowski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03000368A publication Critical patent/MXPA03000368A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03000368A 2000-07-19 2001-07-10 Derivados de pirrolidina como inhibidores de metalproteasa. MXPA03000368A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00114949 2000-07-19
PCT/EP2001/007951 WO2002008185A1 (en) 2000-07-19 2001-07-10 Pyrrolidine derivatives as metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
MXPA03000368A true MXPA03000368A (es) 2004-09-13

Family

ID=8169226

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000368A MXPA03000368A (es) 2000-07-19 2001-07-10 Derivados de pirrolidina como inhibidores de metalproteasa.

Country Status (15)

Country Link
US (3) US20020040146A1 (cg-RX-API-DMAC7.html)
EP (1) EP1303486A1 (cg-RX-API-DMAC7.html)
JP (1) JP3983663B2 (cg-RX-API-DMAC7.html)
KR (1) KR100613196B1 (cg-RX-API-DMAC7.html)
CN (1) CN100406439C (cg-RX-API-DMAC7.html)
AR (1) AR037990A1 (cg-RX-API-DMAC7.html)
AU (2) AU2001278479B2 (cg-RX-API-DMAC7.html)
BR (1) BR0112655A (cg-RX-API-DMAC7.html)
CA (1) CA2415740A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000368A (cg-RX-API-DMAC7.html)
PA (1) PA8522301A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020333A1 (cg-RX-API-DMAC7.html)
UY (1) UY26846A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002008185A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300170B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008185A1 (en) * 2000-07-19 2002-01-31 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as metalloprotease inhibitors
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2004033422A2 (en) 2002-10-07 2004-04-22 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
CN101376656A (zh) * 2007-08-30 2009-03-04 山东轩竹医药科技有限公司 培南衍生物
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2010028051A2 (en) * 2008-09-03 2010-03-11 Florida State University Research Foundation, Inc. Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
BR112017028448A2 (pt) 2015-07-02 2018-08-28 Horizon Orphan Llc análogos de cisteamina resistentes a ado e usos dos mesmos
CN111630032B (zh) * 2018-01-17 2024-06-07 米加尔-加利里研究院有限公司 新型蛋氨酸代谢途径抑制剂
CN111825582B (zh) * 2020-08-12 2022-04-08 江西理工大学 一种以芳基磺酰氯为硫源合成β-硫代羰基化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1281720C (en) * 1984-11-08 1991-03-19 Makoto Sunagawa Carbapenem compounds and production thereof
US4925838A (en) * 1988-03-18 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds
US5317016A (en) * 1991-08-20 1994-05-31 Shionogi Seiyaku Kabushiki Kaisha Pyrrolidylthiocarbapenem derivative
GB9301276D0 (en) * 1993-01-22 1993-03-17 Fujisawa Pharmaceutical Co Bicyclic compounds and their preparation
CA2184101C (en) * 1994-02-25 2005-11-22 Susumu Nakagawa Carbapenem derivatives
HUP9902316A3 (en) * 1996-02-13 2001-12-28 Abbott Lab 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists and pharmaceutical compositions containing them
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
ES2201318T3 (es) * 1996-08-28 2004-03-16 THE PROCTER & GAMBLE COMPANY Inhibidores de metaloproteasas de aminas ciclicas substituidas.
BR0112580A (pt) * 2000-07-19 2003-06-17 Hoffmann La Roche Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos
WO2002008185A1 (en) * 2000-07-19 2002-01-31 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as metalloprotease inhibitors

Also Published As

Publication number Publication date
US6790860B2 (en) 2004-09-14
CA2415740A1 (en) 2002-01-31
BR0112655A (pt) 2003-06-24
US7189756B2 (en) 2007-03-13
KR20030024792A (ko) 2003-03-26
JP3983663B2 (ja) 2007-09-26
US20030199569A1 (en) 2003-10-23
AU2001278479B2 (en) 2007-06-21
CN100406439C (zh) 2008-07-30
JP2004504379A (ja) 2004-02-12
WO2002008185A1 (en) 2002-01-31
ZA200300170B (en) 2004-04-07
UY26846A1 (es) 2002-01-31
KR100613196B1 (ko) 2006-08-18
PA8522301A1 (es) 2002-11-18
EP1303486A1 (en) 2003-04-23
AR037990A1 (es) 2004-12-22
US20020040146A1 (en) 2002-04-04
PE20020333A1 (es) 2002-05-10
US20040242672A1 (en) 2004-12-02
CN1443164A (zh) 2003-09-17
AU7847901A (en) 2002-02-05

Similar Documents

Publication Publication Date Title
MXPA03000223A (es) Derivados de pirrolidina como inhibidores de la enzima conversor de endotelina.
AP2002002407A0 (en) Caspase inhibitors and uses thereof.
MY135841A (en) Novel benzodioxoles
MXPA03011907A (es) Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
EP1554280A4 (en) ANTIDIABETIC HETEROCYCLIC BETA AMINO BINDINGS AS INHIBITORS OF DIPEPTIDYLPEPTIDASE
ATE380175T1 (de) Pyrrolidine als dipeptidyl peptidase inhibitoren
MXPA03011981A (es) 3-fluoruro-pirrolidinas como agentes antidiabeticos.
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
YU29503A (sh) Novi antiholinergici koji se mogu primeniti kao lekovi, kao i postupak za njihovo dobijanje
EP1406872A4 (en) DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES
YU73702A (sh) Karbamatni inhibitori kaspaze i njihova upotreba
PT1556362E (pt) Compostos beta-amino heterocíclicos inibidores da dipeptidil peptidase para o tratamento ou prevenção da diabetes
DK1280797T3 (da) Dipeptidylpeptidase IV-inhibitorer
JO2282B1 (en) Oxazole derivatives
MY147780A (en) Carboxamide compounds and their use as calpain inhibitors
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
SG146658A1 (en) Haloalkyl containing compounds as cysteine protease inhibitors
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
PL1685142T3 (pl) Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
SE9703414D0 (sv) New compounds
NO20005261L (no) Nye heterocyklisk substituerte amider med cystein-protease- inhiberende virkning
MXPA03000368A (es) Derivados de pirrolidina como inhibidores de metalproteasa.
ATE287403T1 (de) 6-phenylbenzonaphthyidine
CA2415681A1 (en) Pyrrolidine derivatives
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal